Updates on ASCO's updated VTE guidelines with a focus on prophylaxis for ambulatory cancer patients

and VTE treatment

Pembrolizumab's latest FDA-approval is discussed

as is pexidartinib's FDA-approval

and finally a comparison of BCOP pass rates by training status